A phase I pharmacokinetic study of PR-104, a hypoxia-activated nitrogen mustard prodrug, in patients with solid tumors

Authors :: Michael B. Jameson
Adam V. Patterson
John Gutheil
William R. Wilson
Danny Rischin
William A. Denny
Mark D. Pegram
Source :: Journal of Clinical Oncology. 26:2562-2562
Publication Year :: 2008
Publisher :: American Society of Clinical Oncology (ASCO), 2008.
Abstract: 2562 Background: This dose-escalation study defined a maximum tolerated dose (MTD) and pharmacokinetics (PK) of PR-104. In preclinical studies PR-104 is converted systemically to the corresponding ...

Subjects :: Cancer Research
business.industry
Pharmacology
Prodrug
Hypoxia (medical)
Nitrogen mustard
chemistry.chemical_compound
Oncology
Pharmacokinetics
chemistry
Maximum tolerated dose
medicine
In patient
medicine.symptom
business

Tools